Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedrich Overkamp

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Geburtshilfe Und Frauenheilkunde|March 27, 2018
Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and PreventionAndreas Schneeweiss, Michael P Lux, Wolfgang Janni, et al.
BMC Cancer|April 13, 2012
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trialCarl Christoph Schimanski, Markus Möhler, Michael Schön, et al.
Der Pathologe|December 1, 2020
[Diagnosis and therapy of tumors with NTRK gene fusion]Albrecht Stenzinger, Cornelis M van Tilburg, Ghazaleh Tabatabai, et al.
Breast (Edinburgh, Scotland)|December 15, 2017
Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registryVolkmar Müller, Naiba Nabieva, Lothar Häberle, et al.
BMC Cancer|November 12, 2020
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in GermanyHanna Huebner, Christian M Kurbacher, Geoffrey Kuesters, et al.
Breast Cancer Research and Treatment|June 11, 2016
Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patientsAlexander Hein, Paul Gass, Christina Barbara Walter, et al.
International Journal of Cancer|January 30, 2019
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trialMelanie Janning, Volkmar Müller, Eik Vettorazzi, et al.
Breast Cancer Research and Treatment|November 21, 2022
Return of individual genomic research results within the PRAEGNANT multicenter registry studyHanna Huebner, Matthias Ruebner, Christian Kurbacher, et al.
Geburtshilfe Und Frauenheilkunde|November 11, 2020
Treatment Landscape and Prognosis After Treatment with Trastuzumab EmtansineElena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
Cancers|October 21, 2020
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with PertuzumabLaura L Michel, Andreas D Hartkopf, Peter A Fasching, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Geburtshilfe Und Frauenheilkunde|March 27, 2018
Update Breast Cancer 2018 (Part 2) - Advanced Breast Cancer, Quality of Life and PreventionAndreas Schneeweiss, Michael P Lux, Wolfgang Janni, et al.
BMC Cancer|April 13, 2012
LICC: L-BLP25 in patients with colorectal carcinoma after curative resection of hepatic metastases: a randomized, placebo-controlled, multicenter, multinational, double-blinded phase II trialCarl Christoph Schimanski, Markus Möhler, Michael Schön, et al.
Der Pathologe|December 1, 2020
[Diagnosis and therapy of tumors with NTRK gene fusion]Albrecht Stenzinger, Cornelis M van Tilburg, Ghazaleh Tabatabai, et al.
Breast (Edinburgh, Scotland)|December 15, 2017
Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registryVolkmar Müller, Naiba Nabieva, Lothar Häberle, et al.
BMC Cancer|November 12, 2020
Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in GermanyHanna Huebner, Christian M Kurbacher, Geoffrey Kuesters, et al.
Breast Cancer Research and Treatment|June 11, 2016
Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patientsAlexander Hein, Paul Gass, Christina Barbara Walter, et al.
International Journal of Cancer|January 30, 2019
Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: A biomarker analysis from the geparquinto phase III neoadjuvant breast cancer trialMelanie Janning, Volkmar Müller, Eik Vettorazzi, et al.
Breast Cancer Research and Treatment|November 21, 2022
Return of individual genomic research results within the PRAEGNANT multicenter registry studyHanna Huebner, Matthias Ruebner, Christian Kurbacher, et al.
Geburtshilfe Und Frauenheilkunde|November 11, 2020
Treatment Landscape and Prognosis After Treatment with Trastuzumab EmtansineElena Laakmann, Julius Emons, Florin-Andrei Taran, et al.
Cancers|October 21, 2020
Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with PertuzumabLaura L Michel, Andreas D Hartkopf, Peter A Fasching, et al.
Pageof 6